Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Aethlon Medical Inc. (AEMD:NASDAQ), powered by AI.
Aethlon Medical Inc. is currently trading at $2.02. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Aethlon Medical Inc. on Alpha Lenz.
Aethlon Medical Inc.'s P/E ratio is -0.2.
“Aethlon Medical Inc. trades at a P/E of -0.2 (undervalued) with modest ROE of -245.9%.”
Ask for details →Aethlon Medical Inc. is a pioneering company in the development of innovative medical technologies aimed at addressing unmet needs in global health. Primarily, the company focuses on developing therapies for life-threatening conditions, including infectious diseases and cancer. A key product in their portfolio is the Hemopurifier, a therapeutic device designed to selectively capture and eliminate harmful viruses, cancer-specific particles, and exosomes from the circulatory system. Aethlon Medical’s groundbreaking work particularly impacts sectors such as medical technology and biotechnology, driving advances in treatments that serve a critical role during pandemics or targeted cancer therapies. The company operates within a crucial segment of the healthcare industry, emphasizing novel treatment methods that hold the potential to transform standard care practices. Based in the United States, Aethlon Medical Inc. contributes significantly to the research and development landscape, ensuring that its cutting-edge solutions meet the rigorous demands of combating complex medical challenges worldwide.
“Aethlon Medical Inc. trades at a P/E of -0.2 (undervalued) with modest ROE of -245.9%.”
Ask for details →Aethlon Medical Inc. (ticker: AEMD) is a company listed on NASDAQ in the Healthcare sector (Medical Devices). It has approximately 14 employees. Market cap is $3M.
The current price is $2.02 with a P/E ratio of -0.24x and P/B of 0.62x.
ROE is -245.88%.